Aveva 250 mg PFS Combipack Injection belongs to the class of estrogen blockers used to treat breast cancer in postmenopausal women. Breast cancer is a type of cancer that develops when the breast cells begin to grow abnormally.

Aveva 250 mg PFS Combipack Injection contains Fulvestrant, which works by inhibiting some of the actions of estrogen (female sex hormone which may help cancer cells grow in women with breast cancer) and reducing the amount that is in the body. Thus, it helps in reducing breast cancer tumour growth.

Aveva 250 mg PFS Combipack Injection will be administered by a healthcare professional; do not self-administer. In some cases, Aveva 250 mg PFS Combipack Injection may cause certain common side effects such as injection site reactions like pain and/or inflammation, weakness, nausea, tiredness, headache or joint and musculoskeletal pain. Most of these side effects of Aveva 250 mg PFS Combipack Injection do not require medical attention and gradually resolve over time. However, if these side effects persist or worsen, please consult your doctor.

If you are allergic to Fulvestrant or any other medicines, please tell your doctor. Aveva 250 mg PFS Combipack Injection is not recommended for pregnant women as it may harm an unborn baby. Aveva 250 mg PFS Combipack Injection is contraindicated for use during lactation. Avoid alcohol consumption while receiving Aveva 250 mg PFS Combipack Injection . Avoid driving or operating machinery if you feel tired or weak after receiving Aveva 250 mg PFS Combipack Injection .

Aveva 250 mg PFS Combipack Injection contains Fulvestrant, used to treat breast cancer in postmenopausal women. Additionally, Aveva 250 mg PFS Combipack Injection may be used in combination with palbociclib to treat women with a type of breast cancer called hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that is locally advanced or has spread to other parts of the body (metastatic).

If you are allergic to Fulvestrant or any other medicines, please tell your doctor. Aveva 250 mg PFS Combipack Injection is not recommended for pregnant women as it may harm an unborn baby. Using effective contraception while being treated with Aveva 250 mg PFS Combipack Injection and for two years after the last dose is advised. Aveva 250 mg PFS Combipack Injection is contraindicated for use during lactation. Avoid alcohol consumption while receiving Aveva 250 mg PFS Combipack Injection . Avoid driving or operating machinery if you feel tired or weak after receiving Aveva 250 mg PFS Combipack Injection .